The alternative medicine industry is expanding rapidly, fueled in large part by the surge of health-related content on social ...
Zacks Investment Research on MSN
Novocure's Optune Lua gets Japan reimbursement for NSCLC treatment
Novocure NVCR recently announced that Japan’s Ministry of Health, Labour and Welfare has approved reimbursement for Optune ...
Incyte announced Friday that the FDA issued a complete response letter for its PD-1 inhibitor Zynyz as a first-line treatment for non-small cell lung cancer.
Independently developed by Junshi Biosciences, JS001sc injection is a subcutaneous injection based on the marketed product toripalimab injection (code: JS001) that is expected to enhance convenience ...
Theralase Technologies (TSXV:TLT) has shown in pre-clinical data that its flagship Rutherrin, when activated by X-Ray, is ...
Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...
Colorectal cancer is increasing in younger patients and is now the leading cause of cancer death in those under age 50, yet those patients lack support.
Now, a Carnegie Mellon University spinout company aims to identify patients at high risk for lung, liver and pancreatic ...
This March, join the Alliance for Clinical Trials in Oncology (Alliance) and the Alliance Foundation Trials (AFT) in spotlighting colorectal cancer, the second leading cause of cancer-related death in ...
Lung cancer remains one of the leading causes of cancer deaths around the world. Among the different types of lung cancer, ...
Emma Operacz was feeling under the weather, and she initially believed she had a UTI. But a series of doctors and medical ...
Professor Chao Zhang's team at Zhujiang Hospital, Southern Medical University, has developed a novel DNA nanomachine-based drug delivery and release strategy aimed at overcoming chemoresistance in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results